- Applied Materials (AMAT, Financial) to announce fiscal Q2 2025 earnings on May 15, 2025.
- Aptevo Therapeutics (APVO) participates in two major conferences in March 2025.
- Aptevo's clinical candidates focus on innovative cancer treatment developments.
Applied Materials (AMAT) has scheduled the release of its fiscal second-quarter 2025 financial results for May 15, 2025. This announcement is keenly anticipated by investors and analysts as they look for insights into the company's performance in the semiconductor equipment and materials sector.
Meanwhile, Aptevo Therapeutics Inc. (APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics, is actively participating in the 37th Annual Roth Conference from March 16-18, 2025, in Dana Point, CA, and the Bio-Europe Springtime Partnering Event from March 17-19, 2025, in Milan, Italy. These events are crucial for Aptevo to showcase its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies.
Aptevo is advancing its clinical candidates, such as Mipletamig, which is in a Phase 1b/2 trial for treating acute myeloid leukemia and has orphan drug designation. Additionally, ALG.APV-527 is under co-development with Alligator Bioscience, targeting multiple solid tumor types and is in a Phase 1 trial.
